Regeneron (REGN) Misses Q1 EPS by 26c
Tweet
Share
E-mail
Get Alerts REGN Hot Sheet
Join SI Premium – FREE
Regeneron (NASDAQ: REGN) reported Q1 EPS of $8.22, $0.26 worse than the analyst estimate of $8.48. Revenue for the quarter came in at $3.03 billion versus the consensus estimate of $3.24 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
